AHS Releases Updated Guidance on Migraine Treatment AHS Releases Updated Guidance on Migraine Treatment
In response to recent advances in drug and device technology for treating migraine, the American Headache Society (AHS) has released new guidance on best preventive and acute strategies for clinical practice.Medscape Medical News
ConclusionsFindings suggest that self-harm behavior and psychiatric disorders are associated with increased ED utilization for subsequent chronic disease-related ED utilization. Chronic disease among adolescent psychiatric patients should be attended to, potentially involving new models of clinical follow-up care.
CONCLUSION: The present findings documented distinct differences in somatosensory function in patients with primary BMS compared to controls, indicating a complex pathophysiology and interaction between impairments in nociceptive processing and psychologic functioning. PMID: 30893407 [PubMed - as supplied by publisher]
Authors: da Silva-Júnior IF, Hartwig AD, Goettems ML, Azevedo MS Abstract AIMS: To assess the presence of dental pain in child abuse victims and to compare the findings to children in the same age group with no history of abuse in a Southern Brazilian city. METHODS: This cross-sectional comparative study was carried out in a convenience sample of 68 child abuse victims from a center for psychologic support and in a comparative group of 204 students from public and private schools, all aged between 8 and 12 years. Data for socioeconomic and demographic variables were collected, and information regarding d...
CONCLUSION: Though local anesthetics provided a significant improvement in pain compared to dry needling, evidence was of low quality, and sensitivity analyses including only double-blinded studies provided no statistically significant difference. Additional studies are needed to confirm these results. PMID: 30893405 [PubMed - as supplied by publisher]
CONCLUSION: These results suggest that strict compliance to the GFD could improve headache in celiac patients with headache, even in those without gastrointestinal symptoms. This observation could provide an additional factor when convincing patients to follow a GFD, thus reducing the morbidity related to CD. PMID: 30893404 [PubMed - as supplied by publisher]
Migraine is a common, disruptive, and often debilitating neurological disorder that the World Health Organization classifies in the highest disability category. Migraine is up to three times more common in women than men. Attacks are commonly triggered by stress, and many migraineurs show signs of sympathetic dysregulation. While the vascular hypothesis for migraine has largely fallen from favor, there are still several lines of evidence to suggest that dysregulation of the dural vasculature may contribute to the initiation of a migraine attack.
Approximately 90% of individuals with headache believe there is at least one trigger, or causal factor, of their headache attacks. The list of headache triggers is extensive, but little is known about how individuals develop such beliefs. The aim of this secondary analysis was to evaluate the degree of information, measured using Shannon entropy, that headache triggers contain and to examine the relationship between joint entropy (i.e., triggers and headache activity) and trigger beliefs. We hypothesized that as information about a headache trigger increased (i.e., an individual was exposed to more states of the trigger), ...
Pain catastrophizing plays a key role in shaping the experience of acute and chronic pain, adverse pain-related outcomes and amplified pain perception. Mindfulness-based stress reduction (MBSR) is an evidence-based program designed to focus attention on the present moment in order to decrease stress, and enhance overall wellbeing. MBSR is believed to benefit patients with chronic pain by increasing pain acceptance and potentially interrupting the link between cognitive and emotional experiences, such as catastrophizing, and the experience of pain.
Erenumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody, approved recently for prevention of episodic and chronic migraine. CGRP is involved in the pathogenesis of migraine, and erenumab works by blocking the CGRP receptors. Common side effects include injection site reactions and constipation. Here we present a patient with hemicrania continua (HC) who responded well to erenumab, while the medication additionally treated her debilitating diarrhea. A 61-year-old female with history of intractable, refractory, chronic, daily, left hemicranial headaches with migrainous features associated with restlessness, ...
A 25-year-old female presented to our clinic with one-year history of retro-orbital orthostatic headaches associated with nausea, vomiting and rare binocular diplopia exacerbated by valsalva, work, and exercise and relieved by lying down. She denied headache upon awakening, photophobia and phonophobia. Her headaches started after returning from a trip to Haiti where she participated in a 30-foot waterfall dive. While there she also developed E. coli diarrheal illness. Two weeks after returning she started having daily headaches which was subsequently evaluated by an otolaryngologist, family medicine practitioner and neurologist.